EFTR

Effector Therapeutics Inc

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Effector Therapeutics Inc (EFTR) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
B+
Factor Score 3.5 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.4
Rev Growth YoY 117.0%
Gross Margin N/M
Price Return 3M 0.0%
Price Return 12M 0.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 69.6
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) B+ (3.5) D+ (1.7) C (2.4) C- (1.9) C (2.5)
2026-08-04 C+ (2.7) B+ (3.5) D+ (1.7) C (2.4) C- (1.9) C (2.5)
2026-08-03 C+ (2.7) C+ (2.8) C- (2.1) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C+ (2.8) C- (2.1) C (2.4) C- (1.9) C (2.4)
2022-12-31 C+ (2.5) A+ (4.9) D+ (1.6) A+ (4.6) D (1.5) B- (3.0)
Page 1 of 2